Operation Pangea brings together health regulators, customs authorities, law enforcement agencies, and private sector partners to tackle the threat posed by global criminal networks
A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).
Forms to make a variation to a manufacturer’s licence.
Immunocore Limited is recalling the batches listed below as a precautionary measure. The recall is due to a decrease in potency identified during stability testing. All other stability test results remain within specification.
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency’s strategic direction over the next three years.
The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives innovation; being a great place to work and providing excellent customer service.
How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Clinical trial applications that need expert advice from a specialist group or committee.
Guidance on labelling for medicinal products used in clinical trials.
Guidance on categorising certain clinical trials as ‘notifiable’.
Guidance on the process for ending a clinical trial.
